| P2093 | author name string | Michael W Kattan | |
| | Nicolas Mottet | |
| | Peter G Hammerer | |
| | Tommaso Prayer-Galetti | |
| P2860 | cites work | PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK | Q24814107 |
| | The impact of informed consent on patient interest in prostate-specific antigen screening | Q30468411 |
| | Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? | Q30471337 |
| | Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 |
| | American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer | Q34325479 |
| | Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy | Q34332665 |
| | Complementary and alternative therapies for advanced prostate cancer | Q34348296 |
| | Radical prostatectomy versus watchful waiting in early prostate cancer | Q34418166 |
| | Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial | Q34469941 |
| | Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer | Q35065401 |
| | Effective testosterone suppression for patients with prostate cancer: is there a best castration? | Q35189745 |
| | Active surveillance: towards a new paradigm in the management of early prostate cancer | Q35648389 |
| | The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry | Q35689357 |
| | Management of prostate-specific antigen relapse in prostate cancer: a European Consensus | Q35782677 |
| | PSA updated: still relevant in the new millennium? | Q36073257 |
| | When and how to use informatics tools in caring for urologic patients | Q36395152 |
| | Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy | Q36439622 |
| | Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. | Q36892107 |
| | Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group | Q39219227 |
| | What should men know about prostate-specific antigen screening before giving informed consent? | Q39479473 |
| | Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range | Q39613073 |
| | The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? | Q39694955 |
| | Validation of a nomogram for predicting positive repeat biopsy for prostate cancer | Q39704723 |
| | 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. | Q40406810 |
| | Risk factors for complications and morbidity after radical retropubic prostatectomy | Q41439204 |
| | Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy | Q44019265 |
| | Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial | Q44070350 |
| | Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration | Q44155877 |
| | Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. | Q44381567 |
| | Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy | Q44546063 |
| | Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate | Q44627250 |
| | Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? | Q45163419 |
| | Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 | Q46105113 |
| | Radical prostatectomy nomograms in black American men: accuracy and applicability | Q46402729 |
| | Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? | Q46441205 |
| | PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy | Q46454930 |
| | Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation | Q47649978 |
| | A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer | Q48030260 |
| | Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. | Q50660841 |
| | Recall and attitudes in patients with prostate cancer. | Q51988199 |
| | ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. | Q52863383 |
| | A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. | Q52935930 |
| | Quality of life after radical prostatectomy or watchful waiting. | Q53417695 |
| | Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 |
| | Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial | Q56804990 |
| P433 | issue | 1 | |
| P304 | page(s) | 11-19 | |
| P577 | publication date | 2006-03-23 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer | |
| P478 | volume | 98 | |